Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.
| Added by | mollevi |
|---|---|
| Last modified by | informatique.ircm |
| Group name | EquipeCG |
| Item Type | Note |
| Note | The following values have no corresponding Zotero field: |
| Tags | _EndnoteXML import |
| Date Added | 2018/07/20 - 10:05:58 |
| Date Modified | 2019/11/28 - 09:11:48 |
| Parent item | A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours |
Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).
U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)
Institut de Recherche en Cancérologie de